When we thought the buyer was Regeneron, I was tentatively optimistic. Yes, a corporation would have your data and intended to profit from it, but that was also true of 23andMe in its heyday.

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

In response to questions about the lawsuit, Regeneron, which is based in Tarrytown in New York's lower Hudson Valley, noted in a statement that the 23andMe bankruptcy auction has been reopened and ...

Her new nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals, the company announced Friday. Then-23andMe CEO Anne Wojcicki in San Francisco on Feb. 20, 2013. Jeff Chiu / AP file ...

Real world data that harnesses deidentified health records is a multi-billion-dollar industry. But what is the value of a ...

Despite Regeneron's pledges to honor 23andMe's privacy policies, more than two dozen states sued to halt the deal, arguing that genetic information is a unique and fundamentally different type of ...

Regeneron Pharmaceuticals (REGN) exits buyout race for 23andMe as Anne Wojcicki's TTAM Research offers a superior $305M bid. Read more here.

In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe’s assets for $256 million, including its personal genome service, research services, biobank, and ...

23andMe filed for Chapter 11 bankruptcy protection in March. Last month, Regeneron announced it would purchase most of 23andMe's assets for $256 million, but it was outbid.